Akademik Veri Yönetim Sistemi
JOURNAL OF ASTHMA, sa.7, ss.756-763, 2018 (SCI-Expanded)
Background: There are limited data regarding the effectiveness of omalizumab in patients with non-allergic asthma. Objective: To evaluate the clinical and functional effectiveness of omalizumab in patients with non-allergic asthma. Methods: The study was a single-center, retrospective chart review of patients with non-allergic asthma who were treated with add-on omalizumab between February 2014 and March 2016. After omalizumab was started, data of the asthma control test (ACT), pulmonary function test, and daily oral corticosteroid (OCS) dosage were collected at baseline, 16weeks, 1year, 2 and 3years (if available). The number of exacerbations/hospitalizations were collected 1 year prior to and 6months/1year after omalizumab. To calculate the total daily dosage of OCS in milligrams, data for 6months/1year prior and after omalizumab treatment were recorded. Results: Thirteen patients were included. After omalizumab, the mean ACT was significantly increased at 16weeks (n = 13, p = 0.002), 1year (n = 7, p = 0.006), and 2years (n = 5, p = 0.006). The mean daily OCS dose was significantly decreased at 16weeks (n = 13, p = 0.001), 1year (n = 7, p = 0.006), and 2years (n = 5, p = 0.04). The mean number of exacerbations and hospitalizations were decreased at the 6th month (n = 13; p = 0.001, p = 0.005) and 1st year (n = 7; p = 0.01, p = 0.02). The mean total quantity of OCS decreased 42% from 1.4 to 0.8 g in the six-month period prior to and post-omalizumab treatment (n = 6, p = 0.02) and decreased 76% from 3.8 to 0.9 g at 1year in the pre vs. post-omalizumab treatment comparison (n = 7, p = 0.01). Six (46.2%) patients responded perfectly and seven (53.8%) partially responded to treatment. Conclusion: Omalizumab can be effective in non-atopic severe asthma.